Increased circulating phenylacetylglutamine concentration elevates the predictive value of cardiovascular event risk in heart failure patients
Journal of Internal Medicine · 2023-10 · 294 (4) · 515-530
DOI: 10.1111/joim.13653 ↗At a glance
Journal article in Journal of Internal Medicine, published online on 2023-05-30. Written by Haoran Wei and 13 co-authors. Institution: Division of Cardiology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuha…. Major MEDLINE topics: Heart Failure. Cited 31 times so far (Crossref); 55 references. The full text is freely available (open access, CC BY-NC-ND 4.0).
Topics: Herzinsuffizienz
Abstract (original language)
Background
Phenylacetylglutamine (PAGln)—a newly discovered microbial metabolite produced by phenylalanine metabolism—is reportedly associated with cardiovascular events via adrenergic receptors. Nonetheless, its association with cardiovascular outcomes in heart failure (HF) patients remains unknown.
Objectives
This study aimed to prospectively investigate the prognostic value of PAGln for HF.
Methods
Plasma PAGln levels were quantified by liquid chromatography‐tandem mass spectrometry. We first assessed the association between plasma PAGln levels and the incidence of adverse cardiovascular events in 3152 HF patients (including HF with preserved and reduced ejection fraction) over a median follow‐up period of 2 years. The primary endpoint was the composite of cardiovascular death or heart transplantation. We then assessed the prognostic role of PAGln in addition to the classic biomarker N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP). The correlation between PAGln levels and β‐blocker use was also investigated.
Results
In total, 520 cardiovascular deaths or heart transplantations occurred in the HF cohort. Elevated PAGln levels were independently associated with a higher risk of the primary endpoint in a dose‐response manner, regardless of HF subtype. Concurrent assessment of PAGln and NT‐proBNP levels enhanced risk stratification among HF patients. PAGln further showed prognostic value at low NT‐proBNP levels. Additionally, the interaction effects between PAGln and β‐blocker use were not significant.
Conclusions
Plasma PAGln levels are an independent predictor of an increased risk of adverse cardiovascular events in HF. Our work could provide joint and complementary prognostic value to NT‐proBNP levels in HF patients.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Division of Cardiology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
- Hubei Key Laboratory of Genetics and Molecular Mechanisms of Cardiological Disorders, Wuhan, China.
- Department of Cardiology, Zhongnan Hospital of Wuhan University, Institute of Myocardial Injury and Repair, Wuhan University, Wuhan, China.
ORCID profiles: Haoran Wei, Junfang Wu, Chen Chen
Cite
APA
Wei, H., Wu, J., Wang, H., Huang, J., Li, C., Zhang, Y., Song, Y., Zhou, Z., Sun, Y., Xiao, L., Peng, L., Chen, C., Zhao, C., & Wang, D. W. (2023). Increased circulating phenylacetylglutamine concentration elevates the predictive value of cardiovascular event risk in heart failure patients. Journal of Internal Medicine, 294(4), 515-530. https://doi.org/10.1111/joim.13653
Vancouver
Wei H, Wu J, Wang H, Huang J, Li C, Zhang Y, et al. Increased circulating phenylacetylglutamine concentration elevates the predictive value of cardiovascular event risk in heart failure patients. Journal of Internal Medicine. 2023;294(4):515-530. doi:10.1111/joim.13653
BibTeX
@article{Wei2023,
author = {Wei, Haoran and Wu, Junfang and Wang, Huiqing and Huang, Jin and Li, Chenze and Zhang, Yuxuan and Song, Yaonan and Zhou, Zhitong and Sun, Yang and Xiao, Lei and Peng, Liyuan and Chen, Chen and Zhao, Chunxia and Wang, Dao Wen},
title = {Increased circulating phenylacetylglutamine concentration elevates the predictive value of cardiovascular event risk in heart failure patients},
journal = {Journal of Internal Medicine},
year = {2023},
volume = {294},
number = {4},
pages = {515--530},
doi = {10.1111/joim.13653}
}
EUVIMED